Author Archives: Margarida Azevedo, MSc

Positive Phase 3b Data for COPD Therapy Anoro Ellipta Presented by GSK

GlaxoSmithKline (GSK) and Innoviva presented positive  results from a Phase 3b study investigating the efficacy and safety of Anoro Ellipta (umeclidinium/vilanterol, or  UMEC/VI) in patients with moderate chronic obstructive pulmonary disease (COPD) who continued to experience symptoms while on tiotropium (bronchodilator) monotherapy. Anoro Ellipta is a combination of a long-acting muscarinic antagonist (LAMA) and a long-acting…

AstraZeneca’s Bevespi Aerosphere Receives FDA Approval for COPD Treatment

AstraZeneca recently announced that its bronchodilator inhalation aerosol medicine Bevespi Aerosphere (glycopyrrolate and formoterol fumarate) has been approved by the U.S. Food and Drug Administration (FDA) for the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), namely, patients suffering from chronic bronchitis and/or emphysema. Bevespi Aerosphere is the…

Short-Term Physical Therapy Program in COPD Patients Improves Quality of Life, Overall Physical Ability, Study Finds

Researchers at the University of Granada (UGR) and Virgen de las Nieves Hospital in Spain revealed that a brief exercise program, from 7 to 10 days, can improve quality of life and physical abilities while minimizing the need for hospitalization in patients with chronic obstructive pulmonary disease (COPD). The research article, “Results…

COPD Study Indicates Certain White Blood Cells May Predict Patients’ Response to Inhaled Corticosteroids

Boehringer Ingelheim recently announced the publication of a new research article detailing the measurement of specific white blood cells, called eosinophils, to prediction the response to inhaled corticosteroids (ICS) in patients with chronic obstructive pulmonary disease (COPD) and a history of exacerbations. The study was developed using data from the…

Best Approaches to Treating Sleep Apnea in COPD Patients to Be Focus of Likely $2.5M Study

The American Sleep Apnea Association (ASAA), a patient-led nonprofit organization to promote sleep health, has received approval from the Patient-Centered Outcomes Research Institute (PCORI)’s board of governors for a three-year, $2.5 million demonstration project into chronic obstructive pulmonary disease (COPD) and sleep apnea, called the O2VERLAP Study. The award for…

COPD Patients Should Have Better, More Routine Assessments of Inhalers, Sunovion Study Reports

Sunovion Pharmaceuticals, a biopharma focused on the development of medical solutions for psychiatric, neurological, and respiratory conditions, recently presented the results of two clinical outcome research studies that investigated the treatment adequacy and inhaler use in chronic obstructive pulmonary disease (COPD) patients. The poster presentation sessions reporting data from…

COPD Bronchodilator Treatment Now Recruiting for European Bioequivalence Study

Lexington, Massachusetts-based Pulmatrix Inc. is enrolling participants for a European pilot bioequivalence study on its product PUR0200, a bronchodilator for the treatment of chronic obstructive pulmonary disease (COPD). The company expects to finish enrollment by the first quarter of 2016 and report initial results in the second quarter. Pulmatrix says its iSPERSE (inhaled…